Analyst Ratings For Portola Pharmaceuticals (NASDAQ:PTLA)
Today, Credit Suisse Group reiterated its Outperform rating on Portola Pharmaceuticals (NASDAQ:PTLA) with a price target of $53.00.
Some recent analyst ratings include
- 2/21/2018-Credit Suisse Group Reiterated Rating of Outperform .
- 1/1/2018-William Blair Reiterated Rating of Buy.
- 12/28/2017-Citigroup Reiterated Rating of Buy.
- 12/1/2017-Goldman Sachs Group initiated coverage with a Buy rating.
- 10/6/2017-Morgan Stanley Reiterated Rating of Overweight.
Recent Insider Trading Activity For Portola Pharmaceuticals (NASDAQ:PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA) has insider ownership of 5.50% and institutional ownership of 86.45%.
- On 12/15/2017 Henry Ward Wolff, Director, sold 12,000 with an average share price of $47.00 per share and the total transaction amounting to $564,000.00.
- On 7/18/2017 John T. Curnutte, Insider, sold 10,000 with an average share price of $65.00 per share and the total transaction amounting to $650,000.00.
- On 7/18/2017 Tao Fu, EVP, sold 5,812 with an average share price of $65.00 per share and the total transaction amounting to $377,780.00.
- On 7/11/2017 Mardi Dier, VP, sold 23,350 with an average share price of $60.00 per share and the total transaction amounting to $1,401,000.00.
- On 6/28/2017 William Lis, CEO, sold 269,299 with an average share price of $55.43 per share and the total transaction amounting to $14,927,243.57.
- On 6/27/2017 Mardi Dier, VP, sold 93,392 with an average share price of $55.46 per share and the total transaction amounting to $5,179,520.32.
- On 6/26/2017 John T. Curnutte, Insider, sold 60,000 with an average share price of $57.88 per share and the total transaction amounting to $3,472,800.00.
Recent Trading Activity for Portola Pharmaceuticals (NASDAQ:PTLA)
Shares of Portola Pharmaceuticals closed the previous trading session at 44.98 down -3.24 6.72% with shares trading hands.